Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer
NCT02747290Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2014
- Primary completion
- Jul 2017
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-BBN-RGD in prostate cancer (PCa), sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized uptake value at 1 year. Status: unknown.
02
Drugs
68Ga-BBN-RGD
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02747290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747290.